Biomedicininės konsultacijos - Company finances
|
EUR
|
2019
From: 2019-09-17
To: 2019-12-31
|
2020
From: 2020-01-01
To: 2020-12-31
|
2021
From: 2021-01-01
To: 2021-12-31
|
2022
From: 2022-01-01
To: 2022-12-31
|
2023
From: 2023-01-01
To: 2023-12-31
|
2024
From: 2024-01-01
To: 2024-12-31
|
2025
From: 2025-01-01
To: 2025-12-31
|
|---|---|---|---|---|---|---|---|
|
Financial data
|
|||||||
| Sales revenue | 5,000 | 9,690 | 15,370 | 8,535 | 11,710 | 9,626 | 15,930 |
| Profit before tax | 250 | 1,630 | 179 | 74 | 119 | -215 | 272 |
| Net profit | 250 | 1,548 | 170 | 70 | 113 | -215 | 256 |
| Equity | 500 | 2,048 | 2,219 | 2,288 | 2,401 | 2,186 | 2,442 |
| Liabilities | - | 82 | 9 | 4 | 8 | 1,661 | 1,696 |
| Non-current assets | 0 | 0 | 1,012 | 1,699 | 918 | 171 | 0 |
| Current assets | 500 | 2,130 | 1,216 | 593 | 1,491 | 3,676 | 4,138 |
| Total assets | 500 | 2,130 | 2,228 | 2,292 | 2,409 | 3,847 | 4,138 |
|
Taxes paid
|
|||||||
| STI taxes | - | - | - | - | 4 | 7 | 817 |
|
Financial indicators
|
|||||||
| Revenue change y/y | - | +93.8% | +58.6% | -44.5% | +37.2% | -17.8% | +65.5% |
| ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. | 50.0% | 72.7% | 7.6% | 3.1% | 4.7% | -5.6% | 6.2% |
| ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. | 50.0% | 75.6% | 7.7% | 3.1% | 4.7% | -9.8% | 10.5% |
| Profit margin Net profit margin. Shows the overall profitability of the company. | 5.0% | 16.0% | 1.1% | 0.8% | 1.0% | -2.2% | 1.6% |
| EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. | 5.0% | 16.8% | 1.2% | 0.9% | 1.0% | -2.2% | 1.7% |
| Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. | - | 0.0 | 0.0 | 0.0 | 0.0 | 0.8 | 0.7 |
| Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. | - | - | - | - | - | - | - |
Sales revenue
See Scoris data in Google Search
Mark Scoris as a favorite source. One click, no registration.
Biomedicininės konsultacijos - Social security debts
The company had no debts to Sodra
Biomedicininės konsultacijos - VMI tax arrears
| From | To | Overdue, € |
|---|---|---|
| 2026-06-18 | 2026-08-13 | 6.27 |
| 2026-05-01 | 2026-06-17 | 3.27 |
| 2026-04-30 | 2026-04-30 | 1.62 |
| 2025-04-02 | 2025-04-28 | 0.78 |
| 2025-03-31 | 2025-04-01 | 0.22 |
VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.
Analysis of the company's financial position
This description was generated by artificial intelligence.
Report if inaccurate.
Biomedicinines konsultacijos, MB (code 305253601) is a Lithuanian small partnership providing business and other management consultancy activities. In the latest financial year, 2025, the company generated revenue of €15.9K and net profit of €256, compared with €9.6K revenue and a net loss of €215 in 2024. This indicates a strong year-on-year recovery, with revenue growth of 65.5% and a return to profitability. Over the two-year period from 2023 to 2025, revenue increased from €11.7K to €15.9K, showing overall growth despite the weaker 2024 result. Profitability remained modest, with a 1.6% net profit margin in 2025.
The balance sheet remained small but stable. At the end of 2025, total assets were €4.1K, equity €2.4K and liabilities €1.7K. The equity ratio stood at 59.0%, while debt-to-equity was 0.69. Asset turnover reached 3.85x, reflecting relatively high revenue generation compared with the asset base. Return on equity was 10.5% and return on assets 6.2%, supported by the improved 2025 result. Short-term assets accounted for the full asset base in 2025, and liabilities remained limited in absolute terms.
The balance sheet remained small but stable. At the end of 2025, total assets were €4.1K, equity €2.4K and liabilities €1.7K. The equity ratio stood at 59.0%, while debt-to-equity was 0.69. Asset turnover reached 3.85x, reflecting relatively high revenue generation compared with the asset base. Return on equity was 10.5% and return on assets 6.2%, supported by the improved 2025 result. Short-term assets accounted for the full asset base in 2025, and liabilities remained limited in absolute terms.